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Abstract: P-glycoprotein (P-gp) is an ATP-dependent transporter localized at the apical 
membrane of the kidney proximal tubules, which plays a role in the efflux of cationic and 
amphipathic endogenous waste products and xenobiotics, such as drugs, into urine. Studies 
in mice deficient in P-gp showed generalized proximal tubular dysfunction similar to the 
phenotype of patients with cystinosis, an autosomal recessive disorder caused by mutations 
in the lysosomal cystine transporter cystinosin. Renal disease in cystinosis is characterized 
by generalized dysfunction of the apical proximal tubular influx transporters (so-called 
renal Fanconi syndrome) developing during infancy and gradually progressing towards 
end-stage renal disease before the 10th birthday in the majority of patients that are not 
treated with the cystine-depleting drug cysteamine. Here, we investigated whether the 
proximal tubular efflux transporter P-gp is affected in cystinosis and whether this might 
contribute to the development of renal Fanconi syndrome. We used conditionally 
immortalized (ci) proximal tubular epithelial cells (ciPTEC) derived from cystinotic 
patients and healthy volunteers. P-gp-mediated transport was measured by using the P-gp 
substrate calcein-AM in the presence and absence of the P-gp-inhibitor PSC833. P-gp 
activity was normal in cystinotic cells as compared to controls. Additionally, the effect of 
cysteamine on P-gp transport activity and phosphate uptake was determined; demonstrating 
increased P-gp activity in cystinotic cells, and further decrease of proximal tubular 
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phosphate uptake. This observation is compatible with the persistence of renal Fanconi 
syndrome in vivo under cysteamine therapy. In summary, P-gp expression and activity are 
normal in cystinotic ciPTEC, indicating that P-gp dysfunction is not involved in the 
pathogenesis of cystinosis.  
Keywords: cystinosis; P-glycoprotein; renal proximal tubular cell; cysteamine 
 
1. Introduction  
Cystinosis is an autosomal recessive disorder caused by bi-allelic mutations in the lysosomal 
cystine transporter cystinosin encoded by the CTNS gene [1]. The most common genetic defect in the 
Northern European population is a large 57 kb deletion, found in up to 60% of the tested alleles [2]. 
While lysosomal cystine accumulation is a key feature in cystinosis, it is still unclear how cystinosin 
dysfunction leads to the clinical phenotype of the disease. The renal phenotype of cystinosis is 
characterized by the development of generalized dysfunction of proximal tubular apical influx 
transporters (renal Fanconi syndrome) in the majority of patients progressing towards end-stage renal 
disease in the first 10 years of life. The cystine-depleting drug, cysteamine, postpones the deterioration 
of renal function. However, renal Fanconi syndrome, when established, is resistant to cysteamine 
treatment, and remains the main source of morbidity, requiring extensive treatment. Whether proximal 
tubular efflux transporters are also affected in cystinosis has never been studied.  
One of the proximal tubular efflux transporters is P-glycoprotein (P-gp), which is an  
ATP-dependent transporter localized at the apical plasma membrane, playing a role in the efflux of 
endogenous waste products and xenobiotics, such as drugs, into urine [3]. Studies in mice genetically 
deficient in P-gp showed generalized proximal tubular dysfunction (e.g., a two-fold increased urine 
flow and a loss of sodium, amino acids, low molecular weight proteins, glucose and calcium into the 
urine) [4], resembling the phenotype of patients with cystinosis. On the other hand, cystinotic ciPTEC 
has been demonstrated to have decreased intracellular ATP levels [5], which can underlie decreased  
P-gp activity.  
Based on these observations, we hypothesized that P-gp expression and/or function can be affected 
by cystinosis and that it might contribute to the pathogenesis of renal Fanconi syndrome in  
this disorder.  
Using ciPTEC from cystinosis patients and healthy subjects, we studied the putative role of P-gp in 
cystinosis by a comprehensive approach including P-gp expression and transporter activity assays, and 
phosphate uptake, either in the presence or absence of cysteamine treatment.  
2. Experimental Section  
2.1. Cell Culture  
Conditionally immortalized human proximal tubule epithelial cell lines (ciPTEC) were established 
and characterized as previously described [5]. Briefly, primary cells were derived from freshly 
collected urine and conditionally immortalized using SV40T antigen and hTERT vector to maintain 
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proliferation as described in detail by Wilmer et al. [6]. In total, clonal ciPTEC were used from  
4 healthy controls and 9 cystinosis patients with known mutations in the CTNS gene (5 homozygous  
57 kb deletion, 4 heterozygous 57 kb deletion combined with other truncating mutations) [5]. All 
cystinosis patients presented with renal Fanconi syndrome. Routinely, cells were maintained at a 
permissive temperature of 33 °C (proliferating cells). To decrease expression of SV40T, cells were 
transferred to 37 °C and allowed to mature for up to 10 days (matured cells). ciPTEC were cultured in 
DMEM-HAM’s F12 medium (Lonza; Basel, Switzerland) supplemented with 10% fetal bovine serum, 
penicillin/streptomycin (100 U/mL, Gibco), ITS (Insulin 5 µg/mL; transferrin 5 µg/mL and selenium  
5 ng/mL, Sigma), epidermal growth factor (10 ng/mL, Sigma), hydrocortisone (36 ng/mL) and  
tri-iodothyronine (40 pg/mL). 
2.2. Quantitative PCR (qPCR) 
To determine P-gp expression, total RNA from ciPTEC was extracted with TRIzolTM total RNA 
isolation reagent (Invitrogen, Merelbeke, Belgium) according to the manufacturer’s protocol. Residual 
DNA was removed using DNAse (Invitrogen) according to the manufacturer’s instructions. 
Approximately 1 μg of total RNA, in the presence of RNase I inhibitor (Invitrogen), was used for 
oligo(dT)-primed first strand cDNA synthesis using M-MLV reverse transcriptase (Invitrogen). qPCR 
was performed in triplicate using the ABI/PRISM 7900 HT Gene Expression Micro Fluidic Card.  
β-actin was used as reference gene. In previous studies, we investigated a number of different 
housekeeping genes in our cell lines and found ß-actin to be most reliable. Primer probe sets for P-gp 
and β-actin were designed by Applied Biosystems (Lot 714363 and 705007 Applied Biosystems, 
Zwijndrecht, The Netherlands). The thermal cycling conditions were 2 min at 50 °C and 10 min at  
95 °C, followed by 40 cycles of 15 sec at 95 °C and 1 min at 60 °C.  
Data are expressed as delta cycle threshold (ΔCT) values, indicating the relative P-gp expression 
levels after correction for β-actin. A Student’s t-test was performed to determine the significance of the 
differences in ΔCt values between patients and controls. 
2.3. Polyacrylamide Gel Electrophoresis and Western Blotting 
For the isolation of membrane vesicles, cell pellets were collected and resuspended in 35 mL  
ice-cold hypotonic buffer (0.5 mM sodium phosphate, 0.1 mM EDTA; pH 7.0) with freshly added 
protease inhibitors (phenylmethylsulfonyl fluoride 100 mM, E64 1 mM, aprotinin 1 mg/mL, leupeptin 
1 mg/mL and pepstatin 1 mg/mL). Cell suspensions were centrifuged for 30 minutes at 100.000xg at  
4 °C (Sorvall Ultra WX-80 surespin 630/17 rotor). The supernatant was discarded and pellets were 
resuspended in 35 mL ice-cold Tris-Sucrose buffer containing 10 mM Tris-Hepes (pH 7.4) and  
250 mM sucrose with added protease inhibitors. The solution was homogenized using a tight-fit 
Douncer (30 strokes) and centrifuged at 500xg for 20 minutes at 4 °C (Eppendorf 5804R) to precipitate 
all cell substances that were not ground by the douncer. Subsequently, the supernatant was centrifuged 
for 60 min at 100.000xg. The vesicle-containing pellet was resuspended in 200 µL Tris-Sucrose buffer 
and dispersed 30 times through a 27-gauge needle. Protein concentration was determined using the 
Lowry protein assay method. Expression of P-gp was analyzed in fractions of 10 µg by Western 
blotting using reduced 6% sodium dodecyl sulphate polyacrylamide gel electrophoreses (SDS-PAGE) 
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and blotting onto a Polyvinylidene Fluoride (PVDF) membrane (Immobilon, Millipore; Bedford, MA, 
USA). Human kidney homogenate in RIPA buffer (Sigma) was used as positive control.  
Membranes were incubated with monoclonal mouse anti-P-gp (1:200 dilution, Abcam) and 
GAPDH (1:5.000 dilution; Abcam, Cambridge, UK) as a house-keeping antigen, followed by 
incubation with goat-anti-mouse-HRP conjugate (1:3000 dilution, Dako) and visualization using Pierce 
ECL Western blotting substrate (Thermo Fisher Scientific, Waltham MA, USA). For  
semi-quantification, the pixel intensity of the immunospecific bands was measured using ImageJ 1.43u 
(National Institutes of Health, Bethesda, MD).  
2.4. Measurement of P-gp Activity  
The transport activity of P-gp was determined using a calcein accumulation assay. Cells were 
cultured to confluency in 96 well plates followed by maturation for 10 days at 37 °C. The experiment 
was initiated by washing the cells twice in 100 µL Hepes-Tris Buffer (pH 7.4, containing NaCl  
132 mM, KCl 0.5 M, CaCl2 1 mM, MgCl2 1 mM, d-Glucose 5.5 mM and HEPES 10 mM). Next, cells 
were incubated for 60 minutes at 37 °C with 100 µL of the lipophylic non-fluorescent P-gp substrate 
calcein-AM (1 µM, Invitrogen) in the presence or absence of the P-gp-inhibitor PSC833 (5 µM; kindly 
provided by Novartis Pharma, Basel, Switzerland) or DMSO vehicle control.  
Additionally, the effect of cysteamine on transport activity was investigated. According to pilots in 
which the optimal concentration and loading time of cysteamine were determined, cells were loaded 
with cysteamine (1 mM) for 2 h before incubation with calcein-AM in presence of cysteamine in  
HT-buffer.  
Transport activity was stopped by using 100 µL ice-cold HEPES-buffer, followed by cell lysation 
with 200 µL 0.1% Triton X-100 in Hepes-Tris buffer. Since calcein-AM is intracellularly metabolized 
into the fluorescent calcein, fluorescence was measured at extinction 485 nm and emission 535 nm 
using a Victor3 Multiplate Reader (Perkin Elmer Inc.). To this end, 150 µL of each sample was 
transferred to a white 96 well micro-titer-plate. 
P-gp transport activity was determined by calculating the ratio between cellular fluorescence in the 
presence of PSC833 or cysteamine and the cellular fluorescence measured in their absence (corrected 
for vehicle). Data are expressed as mean fluorescence ± S.E.M. Mean values were considered to be 
significantly different when p < 0.05 by use of a Student’s t-test.  
2.5. Sodium-Dependent Phosphate Uptake 
Phosphate uptake was performed in confluent monolayers of ciPTEC with 32PO4 (Perkin Elmer, 
Waltham, Mass., USA) as described before [7]. Cells cultured for 10 days at 37 °C were incubated 
with 0.2 mM KH2PO4 (10 μCi/mL) for 5 min in four independent experiments, in the presence of  
137 mM sodium salt or 137 mM N-methyl-D-glucamine to study sodium-dependent transport. Data are 
expressed as mean ± S.E.M. Mean values were considered to be significantly different when  
p < 0.05 by use of a Student’s t-test. 
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3. Results and Discussion  
3.1. P-gp Expression 
Total RNA isolation and whole cell homogenates of control and cystinotic cell lines (see Table 1, 
Figures 1 and 2) were used to study P-gp expression at the gene and protein levels and compared to 
transporter expression in human kidney. Details of the established controls and cystinotic ciPTEC lines 
used in this study, including heterozygous CTNS mutations, were recently published [5]. P-gp mRNA 
expression was assessed by qPCR in triplicate for 9 cystinosis patients and the 4 controls, normalized 
to the average cycle-threshold (C(t)) value for β-actin (C(t) = 18.8 ± 0.8, n = 14) and expressed as 
∆C(t) (Table 1). Expression of P-gp was similar in cystinosis patients and control cells  
(p = 0.30, 0.29, or 0.15 for the homozygous 57 kb deletion, heterozygous deletion, or total cystinosis 
population, respectively). 
Table 1. P-gp mRNA expression in (ci) proximal tubular epithelial cells (ciPTEC) of 
cystinosis patients and healthy controls. Data of 13 samples, measured in triplicate, are 
presented. ∆C(t) values are corrected for the expression of β-Actin, which was used as an 
internal control (mean C(t) β-Actin: C(t) = 18.1 ± 0.9). β-Actin mRNA expressions were 
comparable in ciPTEC from controls (C(t) = 18.1 ± 0.7, n = 4) and the three patient 
populations: homozygous 57 kb deletion C(t) = 18.8 ± 1.2, n = 5; heterozygous 57 deletion 
combined with another mutation C(t) = 19.2 ± 1.0, n = 4. No differences in P-gp expression 
between cystinotic and control ciPTEC were observed. 
ciPTEC ΔCT values p-value 
Healthy controls (n = 4) 10.9 ± 3.5  
Patients with homozygous 57kb deletion (n = 5) 9.2 ± 1.2 0.30 
Patients with heterozygous 57kb deletion combined with 
another mutation (n = 4) 
9.0 ± 1.4 0.35 
All cystinosis patients (n = 9) 9.0 ± 1.3 0.15 
Figure 1. Expression of P-gp (150–170 kDa)) and GAPDH (36 kDa) in membrane vesicles 
of control and cystinotic ciPTEC and total kidney homogenate (HuKid). Representative 
blot of two independent measurements is shown.  
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Protein expression of P-gp in cell lines was analyzed using a mouse monoclonal antibody raised 
against P-gp (C219, purchased from DakoCytomation, the Netherlands). Bands specific for P-gp were 
detected at approximately 150–170 kDa. Figure 1 shows P-gp and the household protein, GAPDH  
(36 kDa), expression in isolated membrane vesicles prepared from cystinotic and control ciPTECs, as 
well as from a total kidney homogenate (Figure 1). Immunospecific bands were semi-quantified by 
pixel scanning densitometry (Figure 2). 
Figure 2. Mean relative protein expression (P-gp/GAPDH) measured by Western blotting 
in ciPTEC of cystinosis patients (red bar) compared to controls (blue bar). p = 0.64.  
 
Overall, no statistical difference between cystinotic and control ciPTEC in the levels of P-gp 
expression was detected. 
3.2 P-gp Transporter Activity in Cystinotic and Control ciPTEC, at Basal Conditions and after 
Incubation with Cysteamine 
The activity of P-gp was determined in matured confluent ciPTEC of cystinosis patients and 
controls, by means of the calcein accumulation assay. The selection of cell lines used in these 
experiments was based on the rate of cell growth, since cell confluency influences P-gp activity [8]. 
All cells were plated at similar densities at experimental start day -1, cultured overnight at 33 °C, and 
transferred to 37 °C at day 0, starting maturation. P-gp activity was measured by incubating cells with 
calcein-AM (1–10 μM) for 60 min at day 7–10 (when the same level of confluency was observed) 
either in the presence or absence of the P-gp inhibitor PSC833 (5 uM). Intracellular calcein 
fluorescences were determined. 
Relative P-gp activity is presented in Figure 3. Both in cystinotic and control ciPTEC, loading of  
1 μM calcein-AM resulted in the highest ratio representing P-gp activity. Based on these results, other 
experiments were conducted with 1 μM calcein-AM. In agreement with unaltered gene and protein 
expression levels, no differences in P-gp activities were found between cystinotic and control cells.  
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Figure 3. Relative P-gp activity after calcein-AM loading. P-gp activity in two different 
cystinotic (red and green bar) and one control (blue bar) ciPTEC line was determined after 
loading the cells with calcein-AM for 60 min (in triplicate) either in the presence of the  
P-gp inhibitory compound PSC833 (5 μM) or vehicle (0.1% DMSO). Relative P-gp 
activity is depicted as ratio of P-gp inhibition (PSC833) over the control condition 
(vehicle). Ratio > 100% indicates inhibition of P-gp activity. Con = control ciPTEC;  
Cys = cystinotic ciPTEC. 
 
Figure 4. Cysteamine effect on relative P-gp activity. P-gp activity in control (blue and 
grey bar; n = 2) and in cystinotic ciPTEC (green and red bar; n = 2) was determined after 
loading the cells with 1 μM calcein-AM for 60 min either in the presence of the P-gp 
inhibitory compound PSC833 (5 μM), or cysteamine (0.01–1 mM). Relative P-gp activity 
is depicted as ratio of P-gp inhibition (PSC833) over the control condition (vehicle; 0.1% 
DMSO). Ratio > 100% indicates inhibition of P-gp activity, whereas a ratio < 100% 
defines increased P-gp activity. Con = control ciPTEC; Cys = cystinotic ciPTEC.  
* p < 0.05; ** p < 0.01; *** p < 0.001 vs. vehicle treated (100%).  
 
Next, to investigate the putative effects of cysteamine on P-gp activity, we performed a  
dose-response experiment with cysteamine concentrations ranging from 0.01–10 mM, including 2 h 
preincubation with identical concentrations. Whereas 0.01–0.1 mM cysteamine are concentrations in 
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the range of those measured in patient’s plasma [9], several fold higher concentrations may be 
expected locally in the kidney tubules due to concentration of the luminal filtrate. As can be observed 
in Figure 4, similar results were obtained for both control and cystinotic cells treated with 0.01, 0.1 and 
1 mM cysteamine, demonstrating that cysteamine slightly, but significantly increases P-gp activity 
(ratio < 100%; p < 0.01). A concentration of 10 mM cysteamine was toxic in all cell lines studied (data 
not shown). We observed no differences in P-gp activity for the three concentrations of cysteamine 
tested, suggesting that the maximal effect was already achieved at the lowest concentration used,  
0.01 mM cysteamine.  
3.3. Consequences of P-gp (Dys)function in ciPTEC 
Sodium-dependent phosphate reabsorption is a differentiated function of renal proximal tubule 
cells, which was determined in cystinotic and control ciPTEC. Both PSC833 and cysteamine 
(pre)incubation resulted in decreased uptake of phosphate (Figure 5). 
Figure 5. Phosphate uptake in cystinotic and control ciPTEC. (A) Uptake of 0.2 mM  
32P-labeled phosphate during 5 min in cystinotic (red bars) and control (blue bars) ciPTEC 
was determined in triplicate with or without preincubation with 5 μM PSC883 or vehicle 
(0.1% DMSO) for 2 h. (B) Cystinotic cells were preincubated with 1 mM cysteamine (red 
bar) or vehicle (blue bar) (normal culture medium) for 1 h. Results are presented as % of 
32PO4 uptake (nmol/μg protein/5 min) *p < 0.05 vs. cystinosis. 
 
The decreased activity of renal proximal tubular apical influx transporters is a key-feature of the 
cystinosis phenotype. However, the activity of efflux transporters, such as P-gp, responsible for the 
excretion of waste products and drugs has not been studied in cystinosis. Based on our previous 
observation in P-gp deficient mice, developing a renal phenotype resembling that of human cystinosis, 
we hypothesized that P-gp activity can be disturbed in patients with cystinosis, which in turn can 
contribute to the pathogenesis of renal Fanconi syndrome. This hypothesis was tested in a recently 
developed human proximal tubular cell model (ciPTEC) derived from urine of cystinosis patients and 
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healthy controls [5]. Compatible to in vivo findings, cystinotic ciPTEC demonstrated decreased 
sodium-dependant phosphate uptake [5]. However, P-gp expression and activity was comparable 
between cystinotic and control cells, indicating that P-gp dysfunction is not involved in the 
pathogenesis of cystinosis.  
Interestingly, treatment with the cystine depleting agent cysteamine slightly enhanced P-gp activity 
in both control and cystinotic ciPTEC. This observation can be of importance for drug dosing in 
cystinosis patients and should be confirmed in vivo, because P-gp is involved in renal clearance of 
numerous drugs, such as the immunosuppressive calcineurin inhibitors, rapamycin and a variety of 
cytostatics [10]. Some clinical studies showed better renal graft survival in patients with cystinosis 
compared to patients with other renal diseases [11,12]. The general belief is that alterations in immune 
response due to cystine accumulation substantiate this observation [12]. Our results might indicate 
another potential mechanism, namely reduced degree in calcineurin inhibitors-induced (CNI) toxicity 
due to the faster elimination of CNI into the proximal tubular lumen by cysteamine mediated P-gp 
stimulation. Whether the observed small increase in P-gp activity is clinically relevant needs to be 
determined, but as shown for single nucleotide polymorphisms in MDR1 leading to gain in function of 
P-gp, as seen for instance for MDR1 polymorphisms in epilepsia treatment [13], this might have an 
impact for pharmacotherapy. The increase in P-gp activity is interesting and possibly related to 
multiple binding sites on P-gp that are allosterically linked [14,15].  
The decreased phosphate uptake in cystinotic and control ciPTEC after P-gp inhibition is 
compatible with our earlier observations in a P-gp knock-out mice model [4]. The reason for this effect 
could be a degree of mitochondrial toxicity because swollen mitochondria and decreased ATP levels 
were observed in P-gp-deficient mice [4]. 
Why cystinosis patients treated with cysteamine maintain their renal Fanconi syndrome is unknown. 
Our previous study demonstrated that cysteamine significantly reduced cystine accumulation in 
cystinotic ciPTEC and increased their intracellular ATP levels [5]. In this study, counter intuitively, we 
demonstrate that cysteamine slightly but significantly decreased cellular phosphate uptake. This 
unexpected observation might underlie the persistence of renal Fanconi syndrome in cystinosis under 
cysteamine treatment and requires further investigation. 
4. Conclusions 
We demonstrate for the first time that proximal tubular efflux transporter P-gp is intact in the 
hereditary proximal tubular disorder cystinosis. The cystine depleting agent cysteamine slightly 
increases P-gp activity, which might be of importance for dosing drugs that are substrates for P-gp in 
patients with cystinosis on cysteamine treatment.  
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